0VAG.LSE Novanta Inc.
- Market cap
- -
- P/E
- 91.5x
- P/B
- -
- ROE
- 4.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0VAG.LSE undervalued?
Graham numberThe Graham number of Novanta Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novanta Inc. fundamental analysis
No fundamental analysis for Novanta Inc. yet.
Novanta Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novanta Inc.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision m…
Full company profileNovanta Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novanta Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 385M | 521M | 614M | 626M | 591M | 707M | 861M | 882M | 949M | 981M | 1.05B |
| Gross Profit | 156M | 212M | 249M | 249M | 232M | 285M | 355M | 395M | 397M | 408M | 445M |
| Operating Income | 41.1M | 64.7M | 79.1M | 71.9M | 59.7M | 82.1M | 107M | 110M | 124M | 117M | 121M |
| EBITDA | 61.4M | 95.5M | 116M | 111M | 98.1M | 126M | 161M | 164M | 166M | 179M | 179M |
| Net Income | 22.0M | 39.8M | 50.9M | 40.8M | 44.5M | 50.3M | 74.1M | 72.9M | 64.1M | 53.8M | 67.3M |
| EPS | 0.63 | 1.13 | 1.43 | 1.15 | 1.25 | 1.41 | 2.06 | 2.02 | 1.77 | 1.47 | 1.63 |
| Balance Sheet | |||||||||||
| Total Assets | 426M | 727M | 720M | 870M | 865M | 1.23B | 1.24B | 1.23B | 1.39B | 1.81B | 2.14B |
| Total Liabilities | 167M | 368M | 351M | 453M | 388M | 707M | 664M | 553M | 643M | 493M | 523M |
| Shareholders' Equity | 259M | 312M | 368M | 417M | 477M | 521M | 578M | 673M | 746M | 1.31B | 1.62B |
| Cash & Short-term Investments | 68.1M | 100M | 82.0M | 78.9M | 125M | 117M | 100M | 105M | 114M | 381M | 719M |
| Total Debt | 86.0M | 243M | 207M | 274M | 255M | 493M | 489M | 405M | 482M | 342M | 286M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 46.0M | 61.3M | 86.1M | 56.3M | 132M | 63.8M | 90.8M | 120M | 159M | 64.1M | 232M |
| Capital Expenditure | 12.4M | 9.09M | 16.3M | 10.7M | 10.5M | 20.0M | 19.6M | 20.0M | 17.2M | 15.6M | 23.1M |
| Free Cash Flow | 33.6M | 52.2M | 69.8M | 45.6M | 121M | 43.8M | 71.1M | 100M | 141M | 48.4M | 209M |
| Ratios | |||||||||||
| ROE | 8.5% | 12.8% | 13.8% | 9.8% | 9.3% | 9.7% | 12.8% | 10.8% | 8.6% | 4.1% | 4.2% |
| ROA | 5.2% | 5.5% | 7.1% | 4.7% | 5.1% | 4.1% | 6.0% | 5.9% | 4.6% | 3.0% | 3.1% |
| Net Profit Margin | 5.7% | 7.6% | 8.3% | 6.5% | 7.5% | 7.1% | 8.6% | 8.3% | 6.8% | 5.5% | 6.4% |
| Debt to Equity | 0.33x | 0.78x | 0.56x | 0.66x | 0.53x | 0.95x | 0.85x | 0.60x | 0.65x | 0.26x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novanta Inc. dividends
Novanta Inc. has not paid dividends in the last 9 fiscal years.
Who owns Novanta Inc.
- Insiders 0.71%
- Institutions 99.29%
- Public & others 0.00%
- Free float 37.5M
Novanta Inc. company profile
- Company name
- Novanta Inc.
- Ticker
- 0VAG.LSE
- ISIN
- CA67000B1040
- Exchange
- London Exchange
- Sector
- Technology
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 3,000
- Fiscal year end
- December
- Address
- 125 Middlesex Turnpike, Bedford, MA, United States, 01730
- Phone
- 781 266 5700
- Website
- novanta.com
About Novanta Inc.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.
Novanta Inc. management
10- Mr. Matthijs GlastraCEO & Chairman of the Board · born 1969
- Mr. Robert J. BuckleyChief Financial Officer · born 1974
- Mr. Alexander ManganielloGeneral Counsel & Corporate Secretary · born 1967
- Mr. Charles G. RavettoCo-Chief Operating Officer of Automation Enabling Technologies · born 1971
- Mr. John LesicaCo-Chief Operating Officer of Medical Solutions · born 1976
- Mr. John Joseph Burke IIChief Accounting Officer & Corporate Controller · born 1982
- Ms. Sarah BetadamChief Information Officer & Chief Information Security Officer
- Ms. Nissia SabriSenior Vice President of Corporate Development
- Mr. Liam WestonChief Human Resources Officer
- Mr. Heinrich DreyerGroup President of Medical Solutions